

BIOMARIN PHARMACEUTICAL INC

Form 4

May 08, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Ajer Jeffrey Robert

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2015

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
SVP, Chief Commercial Of

C/O BIOMARIN PHARMACEUTICAL INC.,, 770 LINDARO ST.

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

SAN RAFAEL, CA 94901

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)		
			Code	V	Amount	(A) or (D)	Price		
Common Stock	04/30/2015 ⁽¹⁾	04/30/2015	A		943	A	\$ 51.2635	43,033	D
Common Stock	05/06/2015	05/06/2015	M		12,502	A	\$ 38.59	55,535	D
Common Stock	05/06/2015	05/06/2015	M		625	A	\$ 21.51	56,160	D
Common Stock	05/06/2015	05/06/2015	M		3,125	A	\$ 21.51	59,285	D
	05/06/2015	05/06/2015	M		2,642	A	\$ 28.23	61,927	D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock								
Common Stock	05/06/2015	05/06/2015	M	5,258	A	\$ 28.23	67,185	D
Common Stock	05/06/2015	05/06/2015	M	808	A	\$ 37.46	67,993	D
Common Stock	05/06/2015	05/06/2015	M	8,671	A	\$ 37.46	76,664	D
Common Stock	05/06/2015	05/06/2015	S	33,631	D	\$ (2) 119.1399	43,033	D
Common Stock	05/06/2015	05/06/2015	S	388	D	\$ (3) 119.195	42,645	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title
Stock Option (right to buy) Common Stock	\$ 38.59	05/06/2015	05/06/2015	M	12,502	11/22/2008 ⁽⁴⁾ 05/21/2018	Common Stock 12,
Stock Option (right to buy) Common Stock	\$ 21.51	05/06/2015	05/06/2015	M	625	11/12/2010 ⁽⁶⁾ 11/11/2020	Common Stock 6
	\$ 21.51	05/06/2015	05/06/2015	M	3,125	11/12/2010 ⁽⁶⁾ 11/11/2020	3,

Stock Option (right to buy) Common Stock									Common Stock	
Stock Option (right to buy) Common Stock	\$ 28.23	05/06/2015	05/06/2015	M	2,642	12/01/2011 ⁽⁷⁾	05/30/2021		Common Stock	2,642
Stock Option (right to buy) Common Stock	\$ 28.23	05/06/2015	05/06/2015	M	5,258	12/01/2011 ⁽⁷⁾	05/30/2021		Common Stock	5,258
Stock Option (right to buy) Common Stock	\$ 37.46	05/06/2015	05/06/2015	M	808	11/08/2012	05/07/2022 ⁽⁷⁾		Common Stock	808
Stock Option (right to buy) Common Stock	\$ 37.46	05/06/2015	05/06/2015	M	8,671	11/08/2012 ⁽⁸⁾	05/07/2022		Common Stock	8,671

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Ajer Jeffrey Robert C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST. SAN RAFAEL, CA 94901			SVP, Chief Commercial Of	

Signatures

/s/ Laura Randall Woodhead,
Attorney-in-Fact

05/08/2015

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person is reporting the purchase of shares of the issuer's Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 1, 2014 to April 30, 2015.
The price in column 4 is an average weighted price. The price actually received ranged from \$119.00 to \$119.39. The reporting person
- (2) shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.
- (3) All shares sold at same price
- (4) Option grant vests 6/48ths on November 22, 2008, and 1/48th on the 22nd day of every month thereafter.
- (5) Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.
- (6) Option grant vests 6/48ths on November 12, 2010, and 1/48th on the 12th day of every month thereafter.
- (7) Option grant vests 6/48ths on December 1, 2011, and 1/48th on the 1st day of every month thereafter.
- (8) Option grant vests 6/48ths on November 8, 2012, and 1/48th on the 12th day of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.